Saxenda vs Ozempic UK: Daily vs Weekly, Cost & Effectiveness

Saxenda (liraglutide 3 mg) and Ozempic (semaglutide 0.5–2 mg) are both GLP-1 receptor agonists — medications that mimic the naturally occurring hormone GLP-1, which regulates appetite, gastric emptying and insulin secretion. Despite working through the same fundamental mechanism, they differ significantly in their pharmacological profile, injection frequency, licensed indications and clinical evidence.

Saxenda (liraglutide 3 mg): - Manufactured by Novo Nordisk - Daily injection via pre-filled pen - Licensed in the UK specifically for chronic weight management in adults with BMI ≥30 (or ≥27 with comorbidities) - Half-life: approximately 13 hours (hence the requirement for daily dosing) - Available on the NHS through Tier 3 weight management services; available privately

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg): - Also manufactured by Novo Nordisk - Weekly injection via pre-filled pen - Licensed in the UK for type 2 diabetes mellitus (not for weight management; Wegovy at 2.4 mg carries the obesity licence) - Half-life: approximately 1 week (hence the once-weekly dosing) - Prescribed off-label for weight management in private clinics; available on NHS for T2DM

Note: Ozempic is not the weight management version of semaglutide — Wegovy (semaglutide 2.4 mg, weekly) is. However, Ozempic at 1–2 mg is widely used off-label for weight loss in private settings in the UK, which is the context for this comparison.

SCALE trials (liraglutide 3 mg / Saxenda): - SCALE Obesity and Prediabetes (participants without diabetes): average weight loss of 8.0% of body weight over 56 weeks at 3 mg liraglutide vs 2.6% for placebo - Approximately 33% of participants achieved ≥10% weight loss - SCALE Diabetes: mean weight loss of 6.0% in participants with type 2 diabetes - A meaningful and statistically significant result, but more modest than newer GLP-1 agents

STEP trials (semaglutide 2.4 mg / Wegovy): - STEP 1 (without diabetes): average weight loss of 14.9% over 68 weeks — nearly double Saxenda's result

Using Ozempic (semaglutide 1–2 mg, not the 2.4 mg weight management dose): - The 1 mg and 2 mg doses used in Ozempic produce somewhat less weight loss than the 2.4 mg Wegovy dose - Real-world UK data and modelling suggest Ozempic 1–2 mg produces weight loss of approximately 8–12% depending on dose and individual response — substantially overlapping with Saxenda at the 2 mg dose

Practical interpretation: - Semaglutide (at the full 2.4 mg weekly weight management dose) is clearly superior to liraglutide for weight loss - When Ozempic is compared to Saxenda specifically (i.e., the lower off-label dose rather than Wegovy), the gap narrows — both are in the 8–12% average weight loss range, though semaglutide at 2 mg appears to have an edge - For maximum weight loss, Mounjaro (tirzepatide) outperforms both

One of the most significant practical differences between Saxenda and Ozempic is injection frequency — and this matters enormously for real-world adherence.

Saxenda: daily injections - Requires 365 injections per year - Injection technique is simple (subcutaneous pen injection into abdomen, thigh or upper arm), but the daily requirement adds a persistent routine burden - Missing a dose more frequently disrupts steady-state blood levels (given the ~13-hour half-life), potentially affecting efficacy and causing rebound appetite - Injection site reactions may be more common due to the frequency - Some UK users report that the daily reminder of treatment is either motivating or intrusive depending on personality

Ozempic/Wegovy: weekly injections - Requires only 52 injections per year - Long half-life means that missing a single dose by a few days has minimal impact on blood levels - The weekly routine is considerably easier to maintain long-term, particularly for people with busy lifestyles, travel demands, or needle anxiety - Adherence data consistently favours weekly over daily injectables across the GLP-1 class

Patient preference research: Stated preference surveys consistently show a strong preference for weekly over daily injections among patients with weight management objectives — typically 70–80% of respondents prefer once-weekly when asked directly.

Needle anxiety: Both products use fine-gauge needles (32–33G) with auto-injection mechanisms designed to minimise discomfort. For people with moderate needle anxiety, the weekly requirement of Ozempic may be easier to manage psychologically than the daily commitment of Saxenda.

For patients using these medications privately — which is the common route for weight management use — cost is a major practical consideration.

Saxenda (liraglutide 3 mg) approximate private costs (April 2026): - The Saxenda pen contains 18 mg liraglutide (18 doses at 1 mg; 6 doses at 3 mg maintenance) - At maintenance dose (3 mg daily): approximately 3 pens per month - Private prescription cost: approximately £130–£200 per month at maintenance dose (3 pens) - Titration phase (starting at 0.6 mg, building to 3 mg over 5 weeks) costs less as lower doses are used

Ozempic (semaglutide 1–2 mg) approximate private costs: - Each Ozempic pen contains 4 doses at the relevant strength - At 1 mg weekly: approximately £80–£130 per month (1 pen) - At 2 mg weekly: approximately £100–£160 per month (1 pen)

Wegovy (semaglutide 2.4 mg) for direct comparison: - Approximately £180–£250 per month at maintenance dose (0.5 mg titration phase is lower)

Summary (approximate monthly medication cost): | Product | Dose | Monthly Cost | | Saxenda | 3 mg daily | £130–£200 | | Ozempic | 1 mg weekly | £80–£130 | | Ozempic | 2 mg weekly | £100–£160 | | Wegovy | 2.4 mg weekly | £180–£250 |

Add prescriber/platform fees of £30–£80/month. Saxenda and Ozempic at lower doses are the most affordable private GLP-1 options in the UK; Wegovy at full dose is the most expensive per month but produces greater weight loss per pound spent in many cases.

The choice between Saxenda and Ozempic depends on your priorities, medical situation, and prescriber's guidance.

Choose Saxenda if: - You prefer a medication with a direct weight management licence rather than off-label prescribing - Your prescriber or clinical pathway prefers it - You have NHS access to Saxenda specifically (it is available on the NHS for weight management, though superseded in many pathways by newer agents) - You are not bothered by daily injections and prefer a shorter-acting medication with more control over daily dosing

Choose Ozempic (or ideally Wegovy) if: - Convenience is a priority — once weekly vs once daily is a meaningful quality-of-life difference - You want access to a potentially higher weight loss ceiling (Wegovy 2.4 mg vs Saxenda 3 mg) - You have type 2 diabetes — Ozempic is the licensed choice and can be prescribed by your GP - You are pursuing maximum simplicity and adherence

Consider Mounjaro (tirzepatide) over both if: - Maximum weight loss efficacy is your priority — SURMOUNT data shows ~20% average weight loss vs ~8% for liraglutide and ~15% for semaglutide 2.4 mg - You have already tried a GLP-1 agonist without adequate response - Cost is acceptable (Mounjaro private costs are similar to Wegovy)

Ultimately, any of these three approved agents represents a significant advance over lifestyle intervention alone. For a patient starting fresh, the combination of once-weekly dosing, greater efficacy at the full dose, and strong UK licensing makes semaglutide (Wegovy) or tirzepatide (Mounjaro) the preferred choices in most private prescribing contexts in 2026.

*This article is for informational and educational purposes only. Do not start, stop or change any medication without guidance from a qualified UK prescriber.*